Vaccine maker Northwest Bio claims it's in the homestretch for its manufacturing expansion in the UK
While the last 2 years have been a roller coaster for Maryland-based vaccine maker Northwest Biotherapeutics — highlighted by a $250,000 fine from the SEC, years operating as a penny stock player with big questions about a cancer drug years in a pivotal study — the biotech says it is still moving ahead with its expansion plans in the UK.
Northwest filed its application for a license to produce at its newest Sawston site, where the first phase of the facility has been built out and the next step will include an on-site inspection by the Medicines and Healthcare Products Regulatory Agency.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.